Clinical Trial: Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Clinical Stage IV Cutaneous Melanoma AJCC v8
Study Type: INTERVENTIONAL
Official Title: Aerosolized Granulocyte-Macrophage Colony Stimulating Factor (Sargramostim) in Combination With Anti-PD1 Therapy for the Treatment of Metastatic Melanoma to the Lung
Brief Summary:
This phase II trial tests the safety, best dose, and effectiveness of inhaled aerosolized sargramostim in combination with standard immunotherapy (nivolumab) for the treatment of patients with melanoma that has spread from where it first started (primary site) to the lung (metastatic to the lung).Sargramostim works to stimulate the immune system by prompting the bone marrow to produce more white blood cells.Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack…
Read more